A controlled inflammation and a regulatory immune system are associated with more favorable prognosis of progressive multifocal leukoencephalopathy

scientific article published on 03 December 2018

A controlled inflammation and a regulatory immune system are associated with more favorable prognosis of progressive multifocal leukoencephalopathy is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S00415-018-9140-0
P698PubMed publication ID30511098

P50authorNobuo SanjoQ52739848
P2093author name stringTakanori Yokota
Yoshiki Sekijima
Toru Tanizawa
Hitoshi Aizawa
Yukiko Shishido-Hara
Saneyuki Mizutani
Yurie Nose
P2860cites workEffects of chloroquine, mefloquine and quinine on natural killer cell activity in vitro. An analysis of the inhibitory mechanismQ41915149
Failure of mefloquine therapy in progressive multifocal leukoencephalopathy: report of two Japanese patients without human immunodeficiency virus infectionQ45353752
Inflammatory progressive multifocal leukoencephalopathy in human immunodeficiency virus-negative patientsQ45406699
Prognostic significance of JC virus DNA levels in cerebrospinal fluid of patients with HIV-associated progressive multifocal leukoencephalopathyQ45510977
Expression of JC virus agnoprotein in progressive multifocal leukoencephalopathy brainQ45731817
Prognostic value of JC virus load in cerebrospinal fluid of patients with progressive multifocal leukoencephalopathyQ45752835
HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathyQ47727845
CD4/CD8 ratio during natalizumab treatment in multiple sclerosis patients.Q50950889
Promyelocytic leukemia nuclear bodies provide a scaffold for human polyomavirus JC replication and are disrupted after development of viral inclusions in progressive multifocal leukoencephalopathy.Q52586074
T cell deficiencies as a common risk factor for drug associated progressive multifocal leukoencephalopathy.Q52689312
Fingolimod-associated PML with mild IRIS in MS: A clinicopathologic study.Q55278001
Clinical Course and Prognostic Factors of Progressive Multifocal Leukoencephalopathy in Patients Treated with Highly Active Antiretroviral TherapyQ58204816
Successful treatment of progressive multifocal leukoencephalopathy with recombinant interleukin-7 and maraviroc in a patient with idiopathic CD4 lymphocytopeniaQ59357367
Cellular and humoral immune response in progressive multifocal leukoencephalopathyQ73892409
Progressive multifocal leukoencephalopathyQ85179611
Progressive multifocal leukoencephalopathy: current treatment options and future perspectivesQ26776236
Restoring function in exhausted CD8 T cells during chronic viral infectionQ28289222
PML diagnostic criteria: consensus statement from the AAN Neuroinfectious Disease SectionQ30613846
Progressive multifocal leukoencephalopathy and other disorders caused by JC virus: clinical features and pathogenesisQ33893285
Nonmyeloablative allogeneic stem cell transplantation for refractory Hodgkin's lymphoma complicated by interleukin-2 responsive progressive multifocal leukoencephalopathyQ34145082
Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairmentQ34857689
Acute and chronic B cell depletion disrupts CD4+ and CD8+ T cell homeostasis and expansion during acute viral infection in miceQ34909225
Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathyQ35675602
JC virus load in cerebrospinal fluid and transcriptional control region rearrangements may predict the clinical course of progressive multifocal leukoencephalopathy.Q35899152
Central nervous system immune reconstitution disease in acquired immunodeficiency syndrome patients receiving highly active antiretroviral treatmentQ36422505
Differences in regulatory sequences of naturally occurring JC virus variantsQ36904520
A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomesQ37135539
JC virus VP1 loop-specific polymorphisms are associated with favorable prognosis for progressive multifocal leukoencephalopathyQ37183930
Detection of JC virus-specific cytotoxic T lymphocytes in healthy individuals.Q37492573
Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 casesQ37714089
Imaging manifestations of progressive multifocal leukoencephalopathyQ37745226
Progressive multifocal leukoencephalopathy and promyelocytic leukemia nuclear bodies: a review of clinical, neuropathological, and virological aspects of JC virus-induced demyelinating diseaseQ37750534
Progressive multifocal leukoencephalopathy and newer biological agentsQ37798242
The expanding family of regulatory B cells.Q38526835
Identification and characterization of mefloquine efficacy against JC virus in vitroQ39877627
Progressive Multifocal Leukoencephalopathy with Balanced CD4/CD8 T-Cell Infiltration and Good Response to Mefloquine Treatment.Q40701415
Role of CD4+ and CD8+ T-cell responses against JC virus in the outcome of patients with progressive multifocal leukoencephalopathy (PML) and PML with immune reconstitution inflammatory syndromeQ41906877
Effect of antimalarial drugs on stimulation and interleukin 2 production of human lymphocytesQ41914397
P433issue2
P921main subjectprogressive multifocal leukoencephalopathyQ704930
P304page(s)369-377
P577publication date2018-12-03
P1433published inJournal of NeurologyQ6295649
P1476titleA controlled inflammation and a regulatory immune system are associated with more favorable prognosis of progressive multifocal leukoencephalopathy
P478volume266

Reverse relations

cites work (P2860)
Q89520913Checkpoint inhibitors and progressive multifocal leukoencephalopathy: friends of foes?
Q92321106Inflammatory Cerebellar PML with a CD4/CD8 Ratio of 2.9 Showed a Favorable Prognosis in a Patient with Rheumatoid Arthritis
Q91830971Progressive Multifocal Leukoencephalopathy: Current Insights

Search more.